trophic
Posted by trophic
October 24, 2026
October 24, 2026

CatalYm Presents Phase 2 Data Showing Visugromab Substantially Enhances the Clinical Benefit of PD-1 Inhibition in Neoadjuvant Bladder Cancer at ESMO 2026

CatalYm Presents Phase 2 Data Showing Visugromab Substantially Enhances the Clinical Benefit...

Read More
trophic
Posted by trophic
October 6, 2026
October 6, 2026

CatalYm to Present Updated GDFATHER-NEO Clinical Data and Highlight Ongoing Phase 2b Visugromab Trials at ESMO 2026

CatalYm to Present Updated GDFATHER-NEO Clinical Data and Highlight Ongoing Phase 2b...

Read More
trophic
Posted by trophic
June 9, 2026
June 9, 2026

CatalYm Appoints Peter Garcia as Chief Financial Officer

CatalYm Appoints Peter Garcia as Chief Financial Officer   Munich, Germany and...

Read More
trophic
Posted by trophic
April 28, 2026
April 28, 2026

CatalYm Appoints Christian S. Schade as Chairman of the Board of Directors

CatalYm Appoints Christian S. Schade as Chairman of the Board of Directors...

Read More
trophic
Posted by trophic
April 23, 2026
April 23, 2026

CatalYm Advances Visugromab into Phase 2/3 Development for Cancer Cachexia with First Patient Dosed

CatalYm Advances Visugromab into Phase 2/3 Development for Cancer Cachexia with First...

Read More
WordPress Cookie Notice by Real Cookie Banner